GELESIS HOLDINGS, INC.
GELESIS HOLDINGS, INC. (GLS): 4 pipeline candidates · ~4 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.9 months
D/E -3.63 · 0% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for GELESIS HOLDINGS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$7.9M
Quarterly Burn
$10.0M
Runway
3.9 mo
Revenue
$1.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| hydrogel candidates for functional constipation | Preclinical |
| hydrogel candidates for nafld/nash | Preclinical |
| hydrogel candidates for type 2 diabetes | Preclinical |
| plenity | Approved |
Frequently asked questions
How many drug candidates are in GELESIS HOLDINGS, INC.'s pipeline?
GELESIS HOLDINGS, INC. (GLS) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is GELESIS HOLDINGS, INC.'s lead drug candidate?
GELESIS HOLDINGS, INC.'s most advanced tracked candidate is hydrogel candidates for functional constipation (Preclinical) for Functional constipation.
What is GELESIS HOLDINGS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, GELESIS HOLDINGS, INC. has approximately 3.9 months of cash runway.
Get the full picture on GELESIS HOLDINGS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.